Navigation Links
Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatism's Congress
Date:6/8/2011

stracts presented

Life-cycle management trials

Trials including structural outcomes in RA

Trials investigating biomarker/ pharmacogenomic predictors of responseCentocor's golimumab

7

2

3

-Abbott's adalimumab

9

-

2

2BMS's abatacept

10

5

2

3Roche/Biogen/Genentech's rituximab

14

2

2

5Roche's tocilizumab

28

3

2

7Novel therapeutics in RA were also showcased at EULAR. Citeline's Associate Director of Autoimmune/Inflammation, Dr. Laura Runkel, found several presentations from Pfizer to be most notable. Pfizer presented results from its ORAL Sync pivotal trial investigating tofacitinib in combination with traditional DMARDs, as well as data from its ORAL Solo trial, evaluating the oral JAK3 kinase inhibitor as monotherapy.  With the presentation of these results, Pfizer has now shared top-line data for all four of its tofacitinib pivotal trials.

"The company has announced plans to file for FDA and EMEA approval in a wide range of treatment combinations and patient populations by the end of 2011, representing the first filing for a biotechnology-derived, targeted oral treatment for RA," comments Dr. Runkel. "If the filings occur as planned, they will put tofacitinib far ahead of its closest competitor, Rigel/AstraZeneca's fostamatinib, whose syk kinase inhibitor is projected to complete pivotal trials in 2013."

About CitelineCiteline (www.citeline.com) provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 18,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors.

All company, brand or product names contained in this document may be trademarks
'/>"/>

SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Decision Resources, one of the ... issues, finds that, over the past 12 months, 25 percent ... , Germany , Italy ... United Kingdom ) have been required to change the ... patients, primarily to reduce costs. Additionally, more than 40 percent ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 /PRNewswire/ ... BDX ) are accelerating the development of new products ... through a new collaboration announced today. This new, three-year commitment ... 1 diabetes (T1D). Many patients with T1D not ... a catheter to be placed in the body for a ...
(Date:6/18/2013)... , June 18, 2013 Today, ... Inc. (NASDAQ: GILD ), Health Management Associates Inc. ... IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ... access these reports free of charge - including full price ... below. Gilead Sciences, Inc. Research Report ...
Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
... for Perforomist(TM) (Formoterol Fumarate) Inhalation ... International ATS Conference --, NAPA, Calif., May ... of the American Thoracic Society (ATS) demonstrate,that concomitant ... FFIS), delivered by nebulization,and Spiriva(R) (tiotropium; TIO) is ...
... be Extended if Patients Receive the ... Most Effective Treatment Identified by ChemoFx, CHICAGO, May ... Assay, a cell-based test that examines the,response of a ... overall survival (OS) in patients with,primary ovarian cancer. Patients ...
Cached Medicine Technology:Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 2Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 3Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 4Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 5Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 6Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer 2Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer 3
(Date:6/18/2013)... ENT and Allergy Associates, LLP (ENTA) does ... opposite. , New York/New Jersey’s premier ear, nose, ... physicians offering superior healthcare to children and adults in ... New York area-only considers adding to its current footprint ... includes the right communities to serve, the right locations ...
(Date:6/18/2013)... June 18, 2013 Internationally acclaimed ... new website, thebestbreast.com, showcasing his unique approach to ... information about his surgical method and highlights the ... on his website, Dr. Tebbetts compares his breast ... methods, Dr. Tebbetts’ method does not necessitate the ...
(Date:6/18/2013)... Belleville, Ill. (PRWEB) June 18, 2013 More ... older are living with HIV/AIDS, according to the Centers for ... don’t know they are infected. In support of National HIV ... Social Security Disability Insurance (SSDI) representation, the CDC ... HIV testing. , The CDC reports about 50,000 new ...
(Date:6/18/2013)... Healthcare Solutions , the ... Management, today announced the appointment of Richard Leonardo ... this position, Leonardo will direct Healthcare Solutions’ national ... growth initiatives. , Recognized in the property and ... brings more than 20 years of experience in ...
(Date:6/18/2013)... New York, NY (PRWEB) June 18, 2013 ... Sinai Medical Center to its “Best Doctors” list, up ... in New York City. The new issue also lists 52 ... network, which continues on a strategic growth trajectory. The “Best ... physicians, appears in the June 24 print issue and is ...
Breaking Medicine News(10 mins):Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 2Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 4Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 5Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3
... hospitals in New York are having a nice holiday with ... program is called Clown Care and believes in the saying ... at New York-Presbyterian Hospital runs this program. It is a ... was introduced by Michael Christensen, co-founder of Big Apple Circus. ...
... of certain stomach drugs may weaken the bones in the ... a new study that advises doctors to consider the risk ... University of Pennsylvania Medical School studied records from the general ... aged over 50 and some had been taking proton pump ...
... At least two children have reportedly died from malnutrition ... //, emblematic of a deep-rooted problem afflicting over 80,000 ... Purushottam of Ateri village died Sunday, two-year-old Chhottu died ... to take special care of him, the activists said., ...
... study of the most widely used osteoporosis drug has found ... without increasing their fracture risk for as long as five ... researchers at the University of California, San Francisco. The research ... spine fractures might be better-off continuing treatment. ,"This ...
... Patna Medical College and Hospital (PMCH) Monday as junior ... despite assurances from the Bihar government. ,The doctors ... on some of them by attendants of a patient. ... assurance to fulfil their demands, Vinod Kumar, one of ...
... switch, the hepatitis C virus turns on human immune ... those defenses by manipulating interaction of key cellular proteins, ... same molecular “on/off switch” controls immunity against many viruses, ... fight viruses, the researchers report. ,In a ...
Cached Medicine News:Health News:Malnutrition Kills Two Kids In Madhya Pradesh 2Health News:Women Faces No Risk on Discontinuation of Osteoporosis Drug 2Health News:Women Faces No Risk on Discontinuation of Osteoporosis Drug 3Health News:Molecular ‘On/Off Switch’ Controls Immune Defenses Against Virus 2
Indications For Usage: ,Laser surgery of the larynx or other areas in close proximity to the tracheal tube using CO2 or KTP laser beam....
Indications For Usage: ,Airway management during pediatric surgical procedures and intensive care....
... The Thermal Angel® is an in-line, ... and IV fluid warming device, capable of ... Thermal Angel® can be used to help ... TA-200 will strive to achieve 38°C (100.4°F) ...
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
Medicine Products: